United States: Broadest Reasonable Interpretation, Not Broadest Possible Interpretation - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

23 May 2023 0 shares 1 views

United States: Broadest Reasonable Interpretation, Not Broadest Possible Interpretation - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq

Published 23 May 2023

On May 2, 2023, the Patent Trial and Appeal Board (PTAB) reversed the Examiner's rejection of a claim directed to a method of creating an immobilized DNA library...

Full Article

United States: It's Time To Change How Antibodies Are Claimed In Patent Strategy - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq 30 May 2023

The US Supreme Court announced its ruling May 18 in favor of Sanofi in its dispute with Amgen over the enablement requirement as it..

More coverage

United States: Supreme Court Denies Cert In Patent Eligibility Cases And The Skinny Label Case - Oblon, McClelland, Maier & Neustadt, L.L.P

Mondaq 25 May 2023

Today the Supreme Court denied cert in GSK v. Teva in which the Solicitor General filed a brief in support of granting cert. The..

United States: Broadest Reasonable Interpretation, Not Broadest Possible Interpretation - Oblon, McClelland, Maier & Neustadt, L.L.P

United States: Broadest Reasonable Interpretation, Not Broadest Possible Interpretation - Oblon, McClelland, Maier & Neustadt, L.L.P

You might like

Related news coverage

United States: It's Time To Change How Antibodies Are Claimed In Patent Strategy - Oblon, McClelland, Maier & Neustadt, L.L.P

Advertisement

More coverage

United States: Supreme Court Denies Cert In Patent Eligibility Cases And The Skinny Label Case - Oblon, McClelland, Maier & Neustadt, L.L.P